- Generic name
- Ibandronic Acid
- Strength
- 150 mg
- Dosage form
- Tablet
- Manufactured by
- Advanced Chemical Industries PLC
Filbone FC Tablet Tablet
About Filbone FC Tablet 150 mg
Filbone FC is a tablet that contains ibandronic acid, a bisphosphonate. Medicines of this type slow the breakdown of bone, which helps bone strength in postmenopausal osteoporosis. The doctor decides how it is used.
There are 13 brands of Ibandronic Acid listed in Bangladesh. The lowest listed price is Bondrix 150 mg Tablet at ৳ 400.00 per unit.
What is Filbone FC Tablet 150 mg?
Filbone FC Tablet is made by Advanced Chemical Industries PLC and contains ibandronic acid 150 mg in tablet form. Ibandronic acid belongs to the bisphosphonate group. These medicines work by reducing the activity of cells that break down bone, so bone loss is slowed. It is used in postmenopausal osteoporosis, where bone mass is low and the risk of fracture is raised. The doctor confirms the condition and decides on treatment. Read the leaflet inside the pack and follow the doctor's instructions.
Uses of Filbone FC Tablet
Filbone FC Tablet is used to treat osteoporosis after menopause, a condition in which bone mass is low and bones are more likely to break. The doctor may confirm it with a bone density scan and a history of fracture. Ibandronic acid, the active ingredient, is a bisphosphonate that reduces bone breakdown. It is not a painkiller and does not relieve symptoms; its purpose is to support bone strength over time.
How to use Filbone FC Tablet
Swallow the tablet whole with a full glass of plain water while sitting or standing upright. Take it before the first food or drink of the day, other than water, and before any other medicine or supplement. Stay upright and do not lie down afterwards. Water is the only drink to take with it. The doctor decides the dose and course; ask the doctor or pharmacist about anything you are unsure of.
Side effects of Filbone FC Tablet
Some people notice indigestion, nausea, diarrhoea, stomach pain, muscle aches, headache or dizziness. Tell your doctor if these bother you or do not settle. Because bisphosphonates can irritate the food pipe and stomach, report pain on swallowing, heartburn, or stomach pain promptly. Serious problems are uncommon, but any new or worrying symptom should be checked by your doctor.
Safety and precautions
Before starting, tell your doctor about any problems with your food pipe or stomach, such as difficulty swallowing, heartburn, gastritis or ulcers, and about low calcium levels, since these need attention first. Your doctor may advise on calcium and vitamin D intake. Filbone FC is not for use in pregnancy, so tell your doctor if you are pregnant, planning a pregnancy or breastfeeding. Do not lie down for a time after taking it. Ask your doctor or pharmacist before use if any of these apply to you.
Frequently asked questions
What kind of medicine is Filbone FC Tablet and what is it used for?
It is a bisphosphonate medicine containing ibandronic acid. It is used to treat osteoporosis after menopause, where bone mass is low and fracture risk is increased. The doctor decides whether it is suitable for you.
Which medicines may interact with Filbone FC Tablet?
Calcium supplements, antacids and some medicines containing aluminium, magnesium or iron can reduce how much ibandronic acid is absorbed. Other oral medicines should be taken after a wait following the tablet. Tell your doctor or pharmacist about everything you take, including supplements, so the timing can be planned.
What do the tablet form and 150 mg strength mean?
The tablet form means it is swallowed with water, not chewed or crushed, and it is taken while upright. The 150 mg strength is the amount of ibandronic acid in each tablet. The doctor decides how the medicine is used, so do not change the dose yourself.
What should I do if I forget or take too much of this medicine?
Ask your doctor or pharmacist for advice about a missed tablet, since timing matters with this medicine. If too much has been taken, contact a doctor or hospital promptly; do not make yourself vomit, and stay upright. The doctor will decide what to do next.
Indications
Treatment of Osteoporosis: Osteoporosis may be confirmed by the finding of low bone mass (T-score <-2.0 SD) and the presence or history of osteoporotic fracture, or a low bone mass (T-score <-2.5 SD) in the absence of documented pre-existing osteoporotic fracture.
Pharmacology
Ibandronic acid is a highly potent bisphosphonate belonging to the nitrogen-containing group of bisphosphonates, which act on bone tissue and specifically inhibit osteoclast activity, It does not interfere with osteoclast recruitment. The selective action of ibandronic acid on bone tissue is based on the high affinity of this compound for hydroxyapatite, which represents the mineral matrix of the bone. Ibandronic acid reduces bone resorption, with no direct effect on bone formation. In postmenopausal women, it reduces the elevated rate of bone turnover towards premenopausal levels, leading to a progressive net gain in bone mass. Daily or intermittent administration of ibandronic acid results in reduced bone resorption as reflected in reduced levels of serum and urinary biochemical markers of bone turnover, increased BMD and a decreased incidence of fractures.
Dosage & Administration
- Tablets should be swallowed whole with a full glass of plain water (180 to 240 ml) while the patient is sitting or standing in an upright position. Patients should not lie down for 60 minutes after taking Ibandronic acid.
- Plain water is the only drink that should be taken with Ibandronic acid. Please note that some mineral waters may have a higher concentration of calcium and therefore should not be used.
- Patients should not chew or suck the tablet because of a potential for oropharyngeal ulceration. Patients should receive supplemental calcium or vitamin D if dietary intake is inadequate. In case a once-monthly dose is missed, patients should be instructed to take one Ibandronic Acid 150 mg tablet the morning after the tablet is remembered unless the time to the next scheduled dose is within 7 days. Patients should then return to taking their dose once a month on their originally scheduled date. If the next scheduled dose is within 7 days, patients should wait until their next dose and then continue taking one tablet once a month as originally scheduled. Patients should not take two 150 mg tablets within the same week.
Interaction
In relation to disposition, no drug interactions of clinical significance are considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not to induce the hepatic cytochrome P450 system in rats. Furthermore, plasma protein binding is low at therapeutic concentrations and ibandronic acid is therefore unlikely to displace other drugs. Ibandronic acid is eliminated by renal excretion only and does not undergo any biotransformation. The secretory pathway appears not to include known acidic or basic transport systems involved in the excretion of other drugs. In a one-year study in postmenopausal women with osteoporosis (BM16549). the incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking Ibandronic Acid 2.5 mg daily or 150mg once monthly. Of over 1500 patients enrolled in study BM 16549 comparing monthly with daily dosing regimens of ibandronic acid, 14% of patients used histamine (H2) blockers or proton pump inhibitors. Among these patients, the incidence of upper gastrointestinal events in the patients treated with Ibandronic Acid 150 mg once monthly was similar to that in patients treated with Ibandronic Acid 2.5 mg daily.
Contraindications
Side Effects
Pregnancy & Lactation
Nursing Mothers: Ibandronic Acid should not be used during lactation. In lactating rats treated with 0.08 mg/kg/day IV. ibandronic acid, the highest concentration of ibandronic acid in breast milk was 8.1 ng/ml and was seen in the first 2 hours after i.v. administration. After 24 hours, the concentration in milk and plasma was similar, and corresponded to about 5 % of the concentration measured after 2 hours.
Precautions & Warnings
Physicians should be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue Ibandronic Acid and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. While no increased risk was observed in controlled clinical trials there have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications. Since NSAIDs and bisphosphonates are both associated with gastrointestinal irritation, caution should be taken during concomitant medication with Ibandronic Acid. Osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates. Most cases have been in cancer patients undergoing dental procedures, but some have occurred in patients with postmenopausal osteoporosis or other diagnoses. Known risk factors for osteonecrosis of the jaw include a diagnosis of cancer, concomitant therapies (e.g., chemotherapy, radiotherapy, corticosteroids), and co-morbid disorders (e.g., anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases have been in patients treated with bisphosphonates intravenously but some have been in patients treated orally. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit-risk assessment.
Overdose Effects
Storage Conditions
Alternative brands of Ibandronic Acid
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.